Research laboratories have not fundamentally changed since the 1960s, says BMG LABTECH. Despite improvements in technology such as high-throughput screening and computational drug design, drug discovery is becoming slower and more expensive over time. Covid-19 highlighted operational vulnerabilities which are driving a fundamental reassessment of strategic priorities. In fact, says… Read More
Listen to this article on the DDW Podcast: High-throughput screens are a recognised hit-finding process but the use of an integrated discipline approach is key to maximising the output from such a screening methodology. Ian Linney and Scott Maidment, Charles River, describe the value of integration of medicinal chemistry in this… Read More
Covid-19 has highlighted the current operational vulnerabilities in pharmaceutical research and in the drug discovery pipeline. Bringing new drugs to the market is still a slow and expensive process, with far too high costs, failure rates and cycle times. With low reproducibility and inefficient processes delaying the path to approval,… Read More
The latest free to listen to DDW podcast episode, titled Flow Cytometry in Drug Discovery, covers an article written by Urmi Roy for DDW, read aloud by Megan Thomas. This article is called “Why flow cytometry in drug discovery is a real life-saver”, in which Roy, Global Product Manager at… Read More
Making good decisions in the drug discovery process requires software to effectively manage the size and complexity of multiparametric datasets. Companies that most quickly and accurately identify key drug discovery parameters will win the race to identify the most appropriate targets and develop medicines to affect them. PerkinElmer has produced… Read More
Carterra, specialist in label-free high throughput antibody screening and characterisation, has closed on a round of equity financing led by PerkinElmer. Current Carterra investors Telegraph Hill Partners and Ballast Point Ventures also participated in the financing round. The Carterra LSA platform for accelerating the discovery of therapeutic antibodies has become… Read More
Mammoth Biosciences has signed agreements with MilliporeSigma and Hamilton Company targeting commercialisation of a high-throughput CRISPR-based SARS CoV-2 test. The test leverages Mammoth’s DETECTR BOOST platform and will provide a sample-to-answer turnkey solution for commercial laboratories to enable an increase in testing capacity. As laboratories face limited capacity and testing… Read More
By Ibis Sanchez-Serrano and Rathnam Chaguturu Mitigation of COVID-19 pandemic requires a combination of effective epidemiological policies and the discovery/development of powerful drugs against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes this disease. This article examines the major initiatives being explored at the public policy level to… Read More
By Dr Karin Bottcher High content screening (HCS) has played a significant role in infectious disease research and drug discovery to date and can be a strong tool in the age of COVID-19 and beyond. With a focus on viral diseases, this article will describe how HCS has been used… Read More
The COVID-19 antiviral race: we're all in this together By Uduak Grace Thomas In response to the COVID-19 pandemic, international scientists from academia and industry have pooled their expertise and resources to identify candidate compounds that inhibit the activity of the SARS-CoV-2 main protease, in order to develop a clinically… Read More
By Richard Gray The recent outbreak of COVID-19 has highlighted the need for fast and efficient development and production of vaccines for a whole gamut of pathogens, old and new. Microfluidics technologies can be used to accelerate the vaccine development process in a number of ways, not least in the… Read More
The CELL CULTURE innovations increasing drug discovery success By Helen Stewart-Miller and Abby George Volume 21 Issue 3 - Summer 2020 'Fail early, fail fast' has been a mantra in the pharmaceutical industry for several years and directly impacts the overall strategy of many drug discovery and development programmes. Yet,… Read More
Guidelines & Recommendations For Analyzing and Interpreting GPCR Second Messenger Data Sponsored by CisBio The question of choosing which methods to use for analyte quantification (signal vs concentration determination, parameters, and format) continues to generate heated debates and divergent understanding. Today, there is still a communication gap between researchers depending… Read More
Unleashing High-Throughput Reaction Screening The Unchained way Sponsored by Unchained Labs A successful high-throughput approach to reaction screening requires rational and systematic exploration of a broad set of variables to achieve optimization expeditiously. There are many types of potential variables that can be screened. Even with the aid of high-throughput… Read More
Stem Cell Differentiation By Dr Lilian Hook Stem cells are extraordinary cells, capable of both self-renewal and differentiation to mature somatic cells in vivo and in vitro (1,2). They have many features and advantages which could revolutionise drug development and healthcare applications. Stem cells offer a limitless, consistent supply of… Read More
Phenotypic Drug Discovery With High Content Screening Sponsored by PerkinElmer Early drug discovery used to be conducted mainly in a target-agnostic fashion, focusing on qualitative readouts from a living system - cells, tissue, or organisms - and asking the question, did this entity affect the phenotype? Target Based or Phenotypic… Read More